Is Cervarix building up a cause for the NIP?

The company which owns ‘Cervarix,’ a uterine cervix cancer vaccine, announced data of an cost-benefit analysis that the drug is more cost-effective than its competing product, ‘Gardasil.’ In the circumstance where it has governmental bidding ahead as the drug was selected as the next year’s vaccine for the National Immunization Program(NIP), spreading a message that Cervarix is more cost-effect...